People

The power of our transpacific partnerships lies at the heart of our investment and company building strategy. We leverage an extensive global network as well as an &#8220;on-the-ground&#8221;, local presence in both Japan and the United States. This enables us to access differentiated sourcing and early-stage investment opportunities for the creation and development of bespoke new biotech companies on both sides of the Pacific. Through this approach, the team gains insights and perspectives that enable it to maximize therapeutic impact for patients around the world, while generating attractive risk-adjusted returns for investors.

Catalys Pacific maximizes its profound global network and robust local presence in Japan to propel its mission of improving patient lives. It is an honor to be a part of that mission.”

Transforming Life Sciences Innovation By Creating And Investing In Global Companies

Catalys Pacific

Home

IPO Archives - Catalys Pacific

Eiji Tanaka

Managing Executive Officer of Mitsubishi Tanabe Pharma Corporation

Mineralys Therapeutics is a private, clinical-stage biopharmaceutical company committed to developing best-in-class, novel therapy for the treatment of hypertension – the leading cause of heart and kidney disease. Mineralys is driven to break the “trial and failure” approach and bring a personalized, targeted approach to the management of hypertension. Through its expertise and focus on the patient, Mineralys aims to change the way hypertension is diagnosed, managed and treated.

A Targeted Approach for the Control of Hypertension

Mineralys - Catalys Pacific

Mineralys

Yoichi Funayama

Senior Executive Officer & General Manager of the Pharmaceutical Business Division of UBE

Kirilys Therapeutics, Inc. (“Kirilys”) was founded by Catalys Pacific as a multi-asset precision oncology company. Kirilys’ lead asset is KRLS-017, a selective and potent Cyclin Dependent Kinase 7 (“CDK7”) inhibitor for multiple oncology indications, in-licensed from UBE. CDK7 has been implicated as a key regulator of both transcriptional addiction and cell cycle dysregulation in tumors and therefore represents an attractive target for therapeutic intervention across a broad range of solid tumors and hematologic malignancies. A best-in-class CDK7 inhibitor could also be optimized using a biomarker strategy to select for patient responders.

Home

Creations

Mineralys

Kirilys